Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04604899 · ClinicalTrials.gov registry record · Phase 2
Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
A Phase 2 study of Retinitis Pigmentosa, sponsored by jCyte.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT04604899: Completed Phase 2 study of Retinitis Pigmentosa, sponsored by jCyte.
NCT04604899 is a Phase 2 study of Retinitis Pigmentosa that has completed, run by jCyte. The registered enrollment target is 30 participants, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04604899, a Phase 2 study of Retinitis Pigmentosa, has completed, sponsored by jCyte.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary objective of the study is to assess the safety of repeat injection of human retinal progenitor cells (jCell) in adult subjects with RP that have previously been treated with jCell.
Primary Outcome
Assessed by percentage of subjects with treatment emergent adverse events
Conditions Studied
Interventions
- BIOLOGICAL human retinal progenitor cells
Study Locations (3)
California
- Gavin Herbert Eye Inst, Univ Cal Irvine - Irvine
- Retina-Vitreous Associates Medical Group - Los Angeles
Massachusetts
- Ophthalmic Consultants of Boston - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2022-03-22 |
| Phase | Phase 2 |
What the finished NCT04604899 record still lists
NCT04604899 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which human retinal progenitor cells is the first listed.
NCT04604899 reports a single indexed study location in California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04604899 about?
NCT04604899 is a clinical study titled "Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa". The primary objective of the study is to assess the safety of repeat injection of human retinal progenitor cells (jCell) in adult subjects with RP that have previously been treated with jCell.
What is the current status of trial NCT04604899?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-12-01. Estimated completion is 2022-03-22.
What conditions does trial NCT04604899 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa.
What interventions are being tested in trial NCT04604899?
The interventions under investigation include: human retinal progenitor cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04604899?
This trial is sponsored by jCyte, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04604899 being conducted?
This trial has 3 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04604899's enrollment target sits among peer trials
30 21st of 37 higher than 16 of 37 other Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
RECRUITING · Phase 2
-
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
COMPLETED · Phase 2
-
Trial of Oral Valproic Acid for Retinitis Pigmentosa
COMPLETED · Phase 2
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI